Abstracts tagged "Dermatology"

Abstract Number: 2154 • ACR Convergence 2022
An Exploratory Phosphoproteomic and Immunohistochemical Analysis of Receptor Tyrosine Kinases and Downstream Signaling Pathways in Systemic Sclerosis Skin
Elizabeth Bundschuh¹, Rebecca Fine², Miruna Carnaru³, Sanchit Kumar⁴, Francis Perry Wilson², Alyssa Williams¹, Shannon Teaw⁴, Ian Odell⁴ and Monique Hinchcliff⁵, ¹Yale University, New Haven, CT, ²Yale School of Medicine, New Haven, CT, ³Hartford Healthcare Medical Group, Rocky Hill, CT, ⁴Yale University School of Medicine, New Haven, CT, ⁵Yale School of Medicine, Westport, CT
Background/Purpose: Receptor tyrosine kinases (RTK) such as epidermal growth factor receptor (EGFR) and others including PDGFRs, FGFRs, and VEGFRs are implicated in systemic sclerosis (SSc)…
Abstract Number: PP15 • ACR Convergence 2022
Coordination of Care by a Healthcare Team for Unexpected and Unusual Side Effects Occurring During a Global Pandemic
Laura Genoves, Arthritis Foundation, Bainbridge Island, WA
Background/Purpose: I am a patient who lives with moderate to severe RA. My quality of life is dependent on medications such as a biologic, DMARDs…
Abstract Number: 0161 • ACR Convergence 2022
Lenabasum, a Cannabinoid Type 2 Receptor Agonist, Exerts Anti-Inflammatory Effects in Dermatomyositis in Th1 Cells
DeAnna Diaz¹, Thomas Vazquez², Nilesh Kodali³, Madison Grinnell⁴, Emily Keyes⁴, Josh Dan⁴, Grant Sprow⁵, Muhammad Bashir⁶, Meena Sharma⁷ and Victoria Werth⁸, ¹Philadelphia College of Medicine, Philadelphia, PA, ²FIU Wertheim College of Medicine, Virginia Beach, VA, ³New Jersey Medical School, Coppell, TX, ⁴Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ⁵Albert Einstein College of Medicine, Philadelphia, PA, ⁶University of Pennsylvania, Philadelphia, PA, ⁷Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁸University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
Background/Purpose: Dermatomyositis (DM) is a chronic, systemic autoimmune disease affecting the skin, muscle, and lungs. Lenabasum, a non-psychoactive cannabinoid type 2 receptor (CB2R) agonist, is…
Abstract Number: 0208 • ACR Convergence 2022
Cutaneous Dermatomyositis Disease Area and Severity Index Activity Score (CDASI-A) and Associated Patient-Reported Outcomes and Biomarkers in a Phase 2 Clinical Trial in Dermatomyositis (DM)
Josh Dan¹, Jay Patel², Grant Sprow³, DeAnna Diaz⁴, Nilesh Kodali⁵, Rui Feng⁶, Barbara White⁷ and Victoria Werth⁸, ¹Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ²Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PN, ³Albert Einstein College of Medicine, Philadelphia, PA, ⁴Philadelphia College of Medicine, Philadelphia, PA, ⁵New Jersey Medical School, Coppell, TX, ⁶University of Pennsylvania, Philadelphia, ⁷SFJ Pharmaceuticals, Towson, MD, ⁸University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
Background/Purpose: Retrospective reviews of clinical databases from two sites have identified strong relationships between patient-reported outcomes and skin activity in DM, as measured by CDASI-A.…
Abstract Number: 0209 • ACR Convergence 2022
Sensitivity of Three Skin-Specific Efficacy Outcomes to Detect Patient- and Physician-Reported Improvement in Overall Skin Disease in Dermatomyositis
Josh Dan¹, Grant Sprow², Josef Concha³, Nilesh Kodali⁴, DeAnna Diaz⁵, Thomas Vazquez⁶, Felix Chin⁷, Barbara White⁸ and Victoria Werth³, ¹Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ²Albert Einstein College of Medicine, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA, ⁴New Jersey Medical School, Coppell, TX, ⁵Philadelphia College of Medicine, Philadelphia, PA, ⁶FIU Wertheim College of Medicine, Virginia Beach, VA, ⁷University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁸SFJ Pharmaceuticals, Towson, MD
Background/Purpose: Variations of the Investigator Global Assessment (IGA) of overall skin disease have been successfully used as a primary efficacy endpoint in registrational clinical trials…
Abstract Number: 0338 • ACR Convergence 2022
Transitioning from Cutaneous to Systemic Lupus Erythematosus: An Analysis of Incidence and Risk Factors
Jeffrey X. Yang¹, Mehmet Hocaoglu², Jose A Meade-Aguilar¹, Alain Sanchez-Rodriguez¹, Mark Denis P Davis³, Hannah Langenfeld⁴, Cynthia Crowson⁵ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²University of Maryland Medical Center, Midtown Campus, Baltimore, MD, ³Mayo Clinic, Rochester, ⁴Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ⁵Mayo Clinic, Eyota, MN
Background/Purpose: Smoking and use of estrogen-containing oral contraceptives (OCP) are SLE risk factors. Data on transitioning from cutaneous lupus erythematosus (CLE) to SLE and potential…
Abstract Number: 0706 • ACR Convergence 2021
Mycophenolate Mofetil and Methotrexate Efficacy in Dermatomyositis
Madison Grinnell¹, Emily Keyes², DeAnna Diaz², Thomas Vazquez³, Rui Feng⁴ and Victoria Werth², ¹Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia VAMC, OMAHA, NE, ²Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA, ³FIU Wertheim College of Medicine, Virginia Beach, VA, ⁴University of Pennsylvania Department of Biostatistics, Philadelphia, PA
Background/Purpose: Treatment of dermatomyositis (DM) typically follows a stepwise sequence starting with either methotrexate (MTX) or mycophenolate mofetil (MMF) after an inadequate response to antimalarial…
Abstract Number: 1026 • ACR Convergence 2021
Factors Impacting Likelihood of Discontinuing Immunosuppression in Adult Dermatomyositis: A Single-Center Study
Sung Kyung Cho¹, Lorinda Chung² and David Fiorentino³, ¹University of Texas Southwestern, Dallas, TX, ²Stanford University, Palo Alto, CA, ³Stanford University, Redwood City, CA
Background/Purpose: Dermatomyositis (DM) is a chronic idiopathic inflammatory myopathy with variable clinical course, but little is known regarding factors associated with remission of disease. We…
Abstract Number: 1170 • ACR Convergence 2021
Establishment and Validation of a Didactic Musculoskeletal Ultrasound Course for Dermatologists Using an Innovative Handheld Ultrasound System
Jakub Grobelski¹, Florian Recker², Pantelis Karakostas¹, Dagmar Wilsmann-Theis³, Wolfgang Hartung⁴, Peter Brossart⁵ and Valentin Schäfer¹, ¹Clinic of Internal Medicine III, Oncology, Haematology, Rheumatology and Clinical Immunology, University Hospital Bonn, Bonn, Germany, ²Centre for Obstetrics and Gynecology, University Hospital Bonn, Bonn, Germany, ³Department for Dermatology and Allery, University Hospital Bonn, Bonn, Germany, ⁴Department of Rheumatology and Clinical Immunology, Asklepios Clinic, Bad Abbach, Germany, ⁵Department of Internal Medicine III, Oncology, Hematology and Rheumatology, University Hospital Bonn, Bonn, Germany
Background/Purpose: In the early detection of arthritis, such as psoriatic arthritis, ultrasound (US) of painful joints plays an important role in diagnosis. Pathological findings can…
Abstract Number: 1178 • ACR Convergence 2021
Implementation of a Dermatologic Manifestations of Connective Tissue Disease Learning Module Including All Skin Tones and Social Determinants of Health for Medical Students: A Pilot Study
Mavra Masood, Fnu Nutan, Julia Nunley and Beth Rubinstein, Virginia Commonwealth University, Richmond, VA
Background/Purpose: There is a dearth of resources for medical students on identifying skin findings of autoimmune disorders in skin of color. Considering how several rheumatologic…
Abstract Number: 1282 • ACR Convergence 2021
Classification of Disease Activity and Damage in Cutaneous Lupus
Laila Abbas, Karabi Nandy and Benjamin Chong, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: The Cutaneous Lupus Disease Area and Severity Index (CLASI) can quantify disease activity and damage in Cutaneous Lupus Erythematosus (CLE). Classification of CLASI scores…
Abstract Number: 1441 • ACR Convergence 2021
Pharmacological Characterization of GLPG3667, a Selective TYK2 Inhibitor for Treatment of Inflammatory Diseases
Roland Blanque¹, Kenji Shoji¹, Mia Jans², Florence Marsais¹, Laetitia Furio¹, Maikel Colli², Céline Cottereaux¹, Christelle David¹, Nicolas Houvenaghel², Isabelle Parent¹, An Van de Water², Laetitia Perret¹, Sofia Alves¹, David Amantini¹, Steven Van der Plas³ and René Galien⁴, ¹Galapagos SASU, Romainville, France, ²Galapagos NV, Mechelen, Belgium, ³Formally Galapagos NV, Mechelen, Belgium, ⁴Galapagos NV, Romainvulle, France
Background/Purpose: Tyrosine kinase 2 (TYK2) is an intracellular kinase that mediates the signaling from type 1 interferon (IFN), interleukin (IL)-12/IL-23 and the IL-10 family of…
Abstract Number: 1495 • ACR Convergence 2021
Multiplexed Profiling of Treatment Naïve Cutaneous Lupus Skin Stratified by Patient Response to Antimalarials
Thomas Vazquez¹, Jay Patel², Daisy Yan³, Emily Keyes⁴, DeAnna Diaz⁵, Yubin Li⁶, Madison Grinnell⁶, Rui Feng⁷ and Victoria Werth³, ¹FIU Wertheim College of Medicine, Virginia Beach, VA, ²Corporal Michael J. Crescenz VAMC, Department of Dermatology, U Penn, Philadelphia, NJ, ³Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁴Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA, ⁵Philadelphia College of Medicine, Philadelphia, PA, ⁶Corporal Michael J. Crescenz VAMC, Department of Dermatology, U Penn, Philadelphia, PA, ⁷University of Pennsylvania Department of Biostatistics, Philadelphia, PA
Background/Purpose: Lupus erythematous (LE) is a systemic autoimmune disease with a variety of cutaneous manifestations. Antimalarials are first-line systemic therapy, yet not all patients respond…
Abstract Number: 1759 • ACR Convergence 2021
An Analysis of Medication Responsiveness Based on Subtype and Race Within a Cohort of Cutaneous Lupus Erythematosus Patients
Emily Keyes¹, Anisha Jobanputra², Madison Grinnell³, Rui Feng⁴, Thomas Vazquez⁵, DeAnna Diaz⁶ and Victoria Werth⁷, ¹Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA, ²Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ³Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia VAMC, OMAHA, NE, ⁴University of Pennsylvania Department of Biostatistics, Philadelphia, PA, ⁵FIU Wertheim College of Medicine, Virginia Beach, VA, ⁶Philadelphia College of Medicine, Philadelphia, PA, ⁷Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Cutaneous lupus erythematosus (CLE) can present in association with or without concomitant SLE, and with skin manifestations varying by subtype – acute CLE, subacute…
Abstract Number: 1774 • ACR Convergence 2021
Blood-based Immune Profiling Combined with Machine Learning Discriminates Psoriatic Arthritis from Psoriasis Patients
Michelle Mulder¹, Xuehui He², Juul van den Reek², Paulo Urbano², Charlotte Kaffa², Xinhui Wang³, Bram van Cranenbroek², Esther van Rijssen², Frank van den Hoogen⁴, Irma Joosten², Wynand Alkema⁵, Elke de Jong², Ruben Smeets², Mark Wenink⁶ and Hans Koenen², ¹Sint Maartenskliniek, Nijmegen, Netherlands, ²Radboud University Medical Center, Nijmegen, Netherlands, ³University of Luxembourg, Belvaux, Luxembourg, ⁴Sint Maartenskliniek, Ubbergen, Netherlands, ⁵Hanze University of Applied Sciences, Groningen, Netherlands, ⁶Sint Maartenskliniek, Malden, Netherlands
Background/Purpose: Early detection of psoriatic arthritis (PsA) in psoriasis (Pso) patients is crucial for timely treatment and prevention of structural joint damage. We aimed to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].